Methods for reducing accumulation of lactate during culturing and method for producing polypeptide

US9670519B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9670519-B2
Application numberUS-201214114525-A
CountryUS
Kind codeB2
Filing dateApr 27, 2012
Priority dateApr 29, 2011
Publication dateJun 6, 2017
Grant dateJun 6, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.

First claim

Opening claim text (preview).

We claim: 1. A method for reducing accumulation of lactate from 5% to 40% in a cell culture of Chinese Hamster Ovary (CHO cells) comprising: a) growing said CHO cells in culture at 37±1° C. for 3-4 days in the presence of zinc salt at a concentration ranging from 0.2 mM to 0.4 mM; b) reducing the temperature in the culture resulting from a) to 31±1° C. and further culturing said cells for 3-4 days, so as to reduce accumulation of lactate by 5% to 40% in the cell culture at the end of the culture period relative to a control which is not supplemental with zinc salt. 2. The method as claimed in claim 1 , wherein the zinc salt is zinc sulphate. 3. The method of claim 2 , wherein the zinc sulphate is zinc sulphate hepta hydrate salt. 4. The method as claimed in claim 1 , wherein the culturing is carried out in a system selected from the group consisting of fed batch culturing, batch culturing, shake flasks and bioreactor.

Assignees

Inventors

Classifications

  • against molecules with a "CD"-designation, not provided for elsewhere · CPC title

  • Metals; Metal chelators · CPC title

  • C12N5/0018Primary

    Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title

  • against receptors for growth factors, growth regulators · CPC title

  • against receptors for cytokines, lymphokines, interferons · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9670519B2 cover?
The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.
Who is the assignee on this patent?
Srivastava Ruchika, Hemdev Sneha Lakshmandas, Bhatnagar Ankur, and 6 more
What technology area does this patent fall under?
Primary CPC classification C12N5/0018. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).